$3516 | SAVE $479 | Single User
$7031 | SAVE $959 | Site License
$10547 | SAVE $1,438 | Enterprise License

EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
[Published by Global Data]

Published by Global Data: 09 Dec 2015 | 17799 | In Stock

Introduction

EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024

Summary

Sjögren’s syndrome (SS) is a chronic systemic autoimmune disease characterized by chronic inflammation of the exocrine glands and is one of the three most common autoimmune diseases in the US. Due to the lack of validated and universally accepted diagnostic criteria for diagnosing SS, a large variation can be seen in the rates of this disease. The three most commonly utilized diagnostic criteria for SS include the Copenhagen criteria, the European classification criteria, and the International Collaborative Clinical Alliances Cohort (SICCA) criteria. The European classification criteria, which were revised by the American-European Consensus Group (AECG), are currently the most widely used diagnostic criteria. Even though no cure currently exists for SS, treatments are used to manage the symptoms and prevent further complications. These might include the use of salivary substitutes and artificial tears, or in the case of secondary SS, treatment of the underlying disease.

GlobalData epidemiologists estimate that within the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan), as shown in Figure 1, the diagnosed prevalent cases of SS will increase from 3,210,390 cases in 2014 to 3,533,298 cases in 2024, at an Annual Growth Rate (AGR) of 1.01% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed prevalent cases of SS in the 7MM. Similarly, the diagnosed prevalent cases of primary Sjögren’s syndrome (pSS) will increase from 2,161,973 cases in 2014 to 2,384,551 cases in 2024, while the diagnosed prevalent cases of secondary Sjögren’s syndrome (sSS) will increase from 1,048,417 cases in 2014 to 1,148,874 cases in 2024. During the forecast period, the proportion of ocular manifestations in the diagnosed prevalent cases of SS will range from a low of 87.00% in the UK and the US to a high of 98.00% in Italy. Similarly, approximately, 93.00-96.00% of prevalent SS cases will experience oral symptoms during the forecast period.

Scope

- The Sjögren’s Syndrome (SS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for SS, which includes both primary Sjögren’s syndrome (pSS) and secondary Sjögren’s syndrome (sSS), in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of pSS, segmented by sex and age (from 18-19 years, then in 10-year age groups), diagnosed prevalent cases of sSS as well as SS and cases of ocular and oral manifestations in SS, in these markets.

- The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SS EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global SS market.

- Quantify patient populations in the global SS market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.

Table of Contents
for EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 4

    1.1 List of Tables 5

    1.2 List of Figures 6

    2 Introduction 7

    2.1 Catalyst 7

    2.2 Related Reports 8

    2.3 Upcoming Reports 8

    3 Epidemiology 9

    3.1 Disease Background 9

    3.2 Risk Factors and Comorbidities 10

    3.3 Global Trends 12

    3.3.1 7MM Diagnosed Prevalent Cases 14

    3.3.2 5EU Diagnosed Prevalent Cases 15

    3.3.3 Japan Diagnosed Prevalent Cases 15

    3.4 Forecast Methodology 15

    3.4.1 Sources Used 19

    3.4.2 Sources Not Used 21

    3.4.3 Forecast Assumptions and Methods 22

    3.5 Epidemiological Forecast for SS (2014-2024) 26

    3.5.1 Diagnosed Prevalent Cases of SS 26

    3.5.2 Age-Specific Diagnosed Prevalent Cases of pSS 32

    3.5.3 Sex-Specific Diagnosed Prevalent Cases of pSS 34

    3.5.4 Age-Standardized Diagnosed Prevalence of pSS 36

    3.5.5 Ocular and Oral Manifestations 38

    3.6 Discussion 39

    3.6.1 Epidemiological Forecast Insight 39

    3.6.2 Limitations of the Analysis 41

    3.6.3 Strengths of the Analysis 41

    4 Appendix 43

    4.1 Bibliography 43

    4.2 About the Authors 47

    4.2.1 Epidemiologists 47

    4.2.2 Reviewers 47

    4.2.3 Global Director of Therapy Analysis and Epidemiology 49

    4.2.4 Global Head of Healthcare 49

    4.3 About GlobalData 50

    4.4 About EpiCast 50

    4.5 Disclaimer 51

List Of Tables
in EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for SS 11

Table 2: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of pSS 16

Table 3: 7MM, Sources Used to Forecast the Oral and Ocular Manifestations of SS 17

Table 4: 7MM, Sources Not Used in the Epidemiological Analysis of SS 22

Table 5: Diagnosed Prevalent Cases of SS, Age ≥18 Years, Both Sexes, N, 2014-2024 31

Table 6: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, 2014 33

Table 7: 7MM, Sex-Specific Diagnosed prevalent Cases of pSS, Age ≥18 Years, N, 2014 35

List Of Figures, Charts and Diagrams
in EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: Diagnosed Prevalence Rate of SS in the 7MM, 2014 14

Figure 2: Case Flow Map for pSS: US, Germany, Italy, UK, and Japan 18

Figure 3: Case Flow Map for pSS: France and Spain 19

Figure 4: 7MM, Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024 27

Figure 5: 7MM, Diagnosed Prevalent Cases of sSS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024 29

Figure 6: 7MM Diagnosed Prevalent Cases of SS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024 32

Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, 2014 34

Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, N, 2014 36

Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of pSS, Age ≥18 Years , 2014 37

Figure 10: 7MM, Ocular and Oral Manifestations of SS in the Diagnosed Prevalent Cases of SS, Age ≥18 Years , 2014 39

Additional Details

Publisher

Global Data

Publisher Information

Reference

17799 | GDHCER104-15

Number of Pages

52

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...